[Treatment of high-risk leukaemia: allograft and immunotherapy].
Traitement des leucémies à haut risque : allogreffe et immunothérapie.
allograft
allogreffe
bone marrow
graft
greffon
immunotherapy
immunothérapie
leucémie à haut risque
leukaemia
moelle osseuse
Journal
Revue de l'infirmiere
ISSN: 1293-8505
Titre abrégé: Rev Infirm
Pays: France
ID NLM: 1267175
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
entrez:
24
11
2019
pubmed:
24
11
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
Leukaemia results from a malignant proliferation of cells in the bone marrow. The prognosis is defined by the disease's biological characteristics. Treatment is based on chemotherapy. In cases of high-risk leukaemia, an allograft may be proposed. The arrival of targeted therapies and immunotherapy has revolutionised the prognosis of the disease. The challenge of the next few years will be to define the place of these therapies.
Identifiants
pubmed: 31757321
pii: S1293-8505(19)30340-9
doi: 10.1016/j.revinf.2019.09.002
pii:
doi:
Types de publication
Journal Article
Langues
fre
Pagination
16-18Informations de copyright
Copyright © 2019 Elsevier Masson SAS. All rights reserved.